Lion Posts Sharp Rise in Quarterly Revenues, Losses | GenomeWeb

NEW YORK, Nov. 8 – Lion Bioscience said Thursday its fiscal second quarter revenues more than doubled to 10.2 million euros ($9.1 million), compared with 4.5 million euros in the year ago period, as revenues from research and development fees tripled.

Such fees accounted for 6.0 million of Lion’s second-quarter revenues, compared with 1.4 million euros a year ago. Revenues from software licenses jumped 38 percent to 4.3 million euros, compared with 3.1 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.